May 03, 2021 8:00am EDT Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer
Apr 01, 2021 8:00am EDT Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development
Feb 17, 2021 8:00am EST Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs
Nov 30, 2020 2:47pm EST HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
Nov 03, 2020 9:00am EST CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer
Aug 04, 2020 12:00pm EDT Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer
Mar 11, 2020 3:27pm EDT Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
Dec 03, 2019 12:30pm EST CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.
Nov 21, 2019 12:00pm EST Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
Nov 18, 2019 12:00pm EST CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure